AquaBounty Facing Environmental Complaint in Panama
By admin,
The Guardian
| 11. 23. 2013
A U.S. company with a Prince Edward Island research facility is facing a complaint in Panama alleging that it is in breach of the country’s environmental regulations.
The Environmental Advocacy Center of Panama submitted a complaint to the country’s National Environmental Authority earlier this week alleging that AquaBounty’s research and development of Genetically Modified (GM) Atlantic salmon is in breach of environmental regulations.
The company produces salmon eggs in P.E.I., which are then shipped to Panama for further research and development.
Sharon Labchuk, of the P.E.I. group “Islanders Say No to Frankenfish”, said she was surprised at the complaint.
“We always assume that because something is as controversial as this is, the proper controls are in place,” said Labchuk. “It’s also very experimental and the risks of anything going wrong are disastrous. They can wipe out the wild salmon population if these fish ever escape and their eggs end up in the wild rivers.”
The National Environmental Authority in Panama conducted an inspection of the AquaBounty operation in 2012 and allegedly found violations that remained uncorrected by the company. Those...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...